Open Access

REVIEW

Jing Shan¹, Catherine King^2,3, Harunor Rashid^3,4, Veysel Kayser^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070851 - 30 December 2025
（This article belongs to the Special Issue: Molecular Targeting Therapy for Anticancer Treatment)
Abstract Objectives: B-cell maturation antigen (BCMA)-targeted antibody–drug conjugates (ADCs) have emerged as promising therapies for relapsed/refractory multiple myeloma (RRMM), but the overall efficacy and safety profile is unclear. This study aimed to synthesize the available evidence on the safety and efficacy of BCMA-ADCs in development for RRMM. Methods: A systematic search was conducted using six bibliographic databases and ClinicalTrials.gov up to November 2024. Studies were eligible if they were human clinical trials or animal studies evaluating BCMA-ADCs and reported efficacy and safety outcomes. Data extraction and quality assessments were conducted using validated tools, including ROBINS-I… More >

View

379

Download

150

Open Access

REVIEW

Sandra Kałużna^1,*, Monika Świerczewska^1,2, Sylwia Ciesiółka¹, Małgorzata Partyka¹, Michał Nowicki¹, Karolina Wojtowicz¹
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070356 - 30 December 2025
（This article belongs to the Special Issue: Identification of potential targets and biomarkers for cancers and the exploration of novel molecular mechanisms of tumorigenesis and metastasis)
Abstract The last research focuses on the role of exosomes in cancer treatment. Exosomes are extracellular vesicles. They can be secreted by cancer cells, and they can modulate chemotherapy sensitivity. Determining exosomal content opens the possibility for guiding treatment strategies for cancer diseases. Exosomal microRNA are considered one of the prime candidates for exosomal biomarkers. Exosomal circular RNAs represent excellent biomarkers for liquid biopsy because of their stability in many types of cancer. Exosomal proteins remain reliable biomarkers also. Exosomes have emerged as promising therapeutic candidates. Their biological properties render them ideal vectors for drug delivery.… More >

View

464

Download

246

Open Access

REVIEW

Giacomo Iovane^1,*, Luca Traman², Michele Maffezzoli^1,3, Giuseppe Fornarini², Domenico Corradi⁴, Debora Guareschi⁴, Matteo Santoni^5,#, Sebastiano Buti^1,#
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523 - 30 December 2025
Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:… More >

Graphic Abstract

View

293

Download

117

Open Access

REVIEW

Abdulrahman K. Sinno¹, Aisha Mustapha¹, Navya Nair¹, Simona Zaami², Lina De Paola², Valentina Billone³, Eleonora Conti³, Giuseppe Gullo^3,*, Pasquale Patrizio⁴
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072176 - 30 December 2025
Abstract Cervical cancer related to human papillomavirus (HPV) is a leading cause of cancer-related mortality among women worldwide. Cancer cells release fragments of their DNA, known as circulating tumor DNA (ctDNA), which can be detected in bodily fluids. A PubMed search using the terms “ctHPV” or “circulating tumor DNA” and “cervical cancer”, limited to the past ten years, identified 104 articles, complemented by hand-searching for literature addressing medico-legal implications. Studies were evaluated for relevance and methodological quality. Detection and characterization of circulating tumor HPV DNA (ctHPV DNA) have emerged as promising tools for assessing prognosis and More >

View

564

Download

355

Open Access

REVIEW

Se Ha Jang^1,2,#, Hyung Seok Kim^3,#, Jung Woo Eun^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072240 - 30 December 2025
Abstract Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal malignancies worldwide. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of gene expression and cancer progression, yet the functional diversity of RP11-derived lncRNAs—originally mapped to bacterial artificial chromosome (BAC) clones from the Roswell Park Cancer Institute—has only recently begun to be appreciated. This mini-review aims to systematically synthesize current findings on RP11-derived lncRNAs in HCC, outlining their genomic origins, molecular mechanisms, and biological significance. We highlight their roles in metabolic reprogramming, microRNA network modulation, and tumor progression, as well as their diagnostic and More >

View

298

Download

138

Open Access

REVIEW

Wen-Shou Tan^1,#, Hsuan Kuo^2,#, Chang-Ge Jiang¹, Mei-Han Lu¹, Yi-He Lu¹, Yung-Li Wang¹, Ching-Shuen Wang¹, Thi Thuy Tien Vo³, I-Ta Lee^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070871 - 30 December 2025
Abstract This narrative review examines recent advances in salivary biomarkers for oral squamous cell carcinoma (OSCC), a major subtype of oral cancer with persistently low five-year survival rates due to delayed diagnosis. Saliva has emerged as a noninvasive diagnostic medium capable of reflecting both local tumor activity and systemic physiological changes. Various salivary biomarkers, including microRNAs, cytokines, proteins, metabolites, and exosomes, have been linked to oncogenic signaling pathways involved in tumor progression, immune modulation, and therapeutic resistance. Advances in quantitative polymerase chain reaction, mass spectrometry, and next-generation sequencing have enabled comprehensive biomarker profiling, while point-of-care detection More >

View

252

Download

117

Open Access

REVIEW

Ashok Kumar Sah^1,*, Ranjay Kumar Choudhary^1,2, Velilyaeva Alie Sabrievna³, Karomatov Inomdzhon Dzhuraevich⁴, Anass M. Abbas⁵, Manar G. Shalabi⁵, Nadeem Ahmad Siddique⁶, Raji Rubayyi Alshammari⁷, Navjyot Trivedi⁸, Rabab H. Elshaikh¹
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068238 - 30 December 2025
（This article belongs to the Special Issue: Advances in Pathology, Early Diagnosis and Therapeutic Strategies for Breast Cancer)
Abstract Male breast cancer (MBC) is rare, representing 0.5%–1% of all breast cancers, but its incidence is increasing due to improved diagnostics and awareness. MBC typically presents in older men, is human epidermal growth factor receptor 2 (HER2)-negative and estrogen receptor (ER)-positive, and lacks routine screening, leading to delayed diagnosis and advanced disease. Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations. Clinically, it may resemble gynecomastia but usually appears as a unilateral, painless mass or nipple discharge. Advances in imaging and liquid biopsy have More >

View

511

Download

169

Open Access

REVIEW

Shujie Yin¹, Zong Li¹, Wen-Bin Ou^1,2,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069049 - 30 December 2025
（This article belongs to the Special Issue: The Evolving Landscape of Cancer Treatment: Molecular Insights and Immunotherapeutic Breakthroughs)
Abstract Ferroptosis is an iron-dependent, excessive lipid peroxidation-driven form of regulated cell death. The core mechanisms of ferroptosis include lipid peroxidation cascade, System X_c⁻-glutathioneglutathione peroxidase 4 axis, iron and lipid metabolism chaos, the NAD(P)Hferroptosis suppressor protein 1—ubiquinone axis, and GTP cyclohydrolase 1 tetrahydrobiopterin-dihydrofolate reductase axis. Cuproptosis is triggered by copper ions and involves ferredoxin 1-mediated aggregation of lipoylated proteins, differing fundamentally from ferroptosis. Both ferroptosis and cuproptosis exhibit dual roles (promote or inhibit) in cancers. And the sensitivity of different cancer types to ferroptosis varies, which may depend on special metabolic signatures (e.g., E-cadherin loss causes epithelial–mesenchymal More >

Graphic Abstract

View

1210

Download

566

Open Access

REVIEW

Dongchi Cai^1,2,#, Jialin Ji^3,#, Chunhui Yang^1,*, Hong Cai^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.071152 - 30 December 2025
（This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
Abstract Metabolic reprogramming involving branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—is increasingly recognized as pivotal in cancer progression, metastasis, and immune modulation. This review comprehensively explores how cancer cells rewire BCAA metabolism to enhance proliferation, survival, and therapy resistance. Tumors manipulate BCAA uptake and catabolism via high expression of transporters like L-type amino acid transporter 1 (LAT1) and enzymes including branched chain amino acid transaminase 1(BCAT1), branched chain amino acid transaminase 2 (BCAT2), branched-chain alpha-keto acid dehydrogenase (BCKDH), and branched chain alpha-keto acid dehydrogenase kinase (BCKDK). These alterations sustain energy production, biosynthesis, redox homeostasis, and oncogenic… More >

View

409

Download

230

Open Access

ARTICLE

Rabindranath Bera^1,#, Yotaro Ochi^2,3, Ying-Jung Huang¹, Ming-Chung Kuo^1,4, Kenichi Yoshida⁵, Seishi Ogawa², Lee-Yung Shih^1,4,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070259 - 30 December 2025
（This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Abstract Background: Breakpoint Cluster Region-Abelson (BCR::ABL1) fusion protein is essential in the pathogenesis of chronic myeloid leukemia (CML); however, the chronic-to-blast phase transformation remains elusive. We identified novel kinesin light chain 2 (KLC2) mutations in CML-myeloid blast phase patients. We aimed to examine the functional role of KLC2 mutations in leukemogenesis. Methods: To evaluate the biological role of KLC2 mutants (MT) in CML cells, we expressed KLC2-MT in different human CML cell lines harboring BCR::ABL1 and performed immunoblot, immunofluorescence, cell proliferation, differentiation, and apoptosis; Tyrosine kinase inhibitor (TKI)-drug activities; and clonogenic assays for in vitro functional analyses. We co-expressed KLC2-MT… More >

View

234

Download

83

Open Access

ARTICLE

Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025
（This article belongs to the Special Issue: Cancer Mutations: From Mechanisms to Targeted Therapy)
Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

View

233

Download

95

Open Access

ARTICLE

Cheng-Hsun Chuang^1,2,3,#, Ping-Kun Tsai^3,4,5,6,#, Shih-Wen Kao^7,8, Yu-Hsun Wang^8,9,*, Chao-Bin Yeh^1,2,3,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.072875 - 30 December 2025
（This article belongs to the Special Issue: Therapeutic Challenges in Targeting Cell Death)
Abstract Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI). Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user… More >

Graphic Abstract

View

239

Download

59

Open Access

ARTICLE

Sarra B. Shakartalla^1,2,3, Iman M. Talaat^1,2,4,*, Nival Ali¹, Shahenaz S. Salih^1,5, Zainab M. Al Shareef^1,2, Noura Alkhayyal⁶, Riyad Bendardaf^2,7,*, Sameh S. M. Soliman^1,8,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070808 - 30 December 2025
（This article belongs to the Special Issue: Discover Biomarkers for Personalized Oncology)
Abstract Objectives: Breast cancer (BC) is the leading cause of cancer-related mortality in women, largely due to metastasis. This study aims to explore the role of purine nucleoside phosphorylase (PNP), a key enzyme in purine metabolism, in the aggressiveness and metastatic behavior of BC. Methods: A comprehensive analysis was performed using in silico transcriptomic data (n = 2509 patients), immunohistochemical profiling of BC tissues (n = 103), and validation through western blotting in multiple BC cell lines. Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and… More >

View

254

Download

96

Open Access

ARTICLE

Xiangmei Ye^1,2,3, Baoyi Yang⁴, Xin Zhang⁵, Luyuan Yang¹, Likun Zhang⁵, Qin Ren¹, Xiaobing Li¹, Leiguang Feng¹, Lanlan Wei^3,6,7,*, Peng Song¹, Yuqing Ye⁸, Xin Lian⁹, Yujuan Gao⁹, Haidi Tang¹, Zhiyu Liu¹
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068814 - 30 December 2025
（This article belongs to the Special Issue: The Metabolic Reprogramming and Its Intervention in Tumorigenesis)
Abstract Objectives: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia and Philadelphia-like B-cell acute lymphoblastic leukemia (Ph+/Ph-like ALL) constitute the majority of relapsed/refractory B-ALL (R/R B-ALL) cases, highlighting an urgent need to discover new therapeutic targets. This study aims to elucidate the mechanisms underlying poor prognosis in Ph+/Ph-like ALL through transcriptome sequencing and functional cytological assays, with the goal of informing new clinical treatment strategies. Results: Transcriptomic analysis of Ph+/Ph-like ALL patients revealed that low expression of P2X Purinoceptor 1 (P2RX1) was associated with unfavorable outcomes. Specifically, patients with poor prognosis and low P2RX1 expression exhibited downregulation of… More >

View

400

Download

152

Open Access

ARTICLE

Xiaopan Zou^1,2, Meiyang Sun³, Xin Jiang¹, Jingze Yu², Xiaomeng Li^4,*, Bingyu Nie^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.066662 - 30 December 2025
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Objective: Triple-negative breast cancer (TNBC) is highly aggressive and lacks an effective targeted therapy. This study aimed to elucidate the functions and possible mechanisms of action of zinc finger miz-type containing 2 (ZMIZ2) and minichromosome maintenance complex component 3 (MCM3) in TNBC progression. Methods: The relationship between ZMIZ2 expression and clinical characteristics of TNBC was investigated. In vitro and in vivo experiments were performed to investigate the role of ZMIZ2 dysregulation in TNBC cell malignant behaviors. The regulatory relationship between ZMIZ2 and MCM3 was also explored. Transcriptome sequencing was performed to elucidate possible mechanisms underlying the ZMIZ2/MCM3… More >

View

225

Download

55

Open Access

ARTICLE

Wendong Jia^#, Ting Zhang^#, Ziying Zhang, Lingzhi Wu, Xihao Fu, Zhenxin Wang^*, Ni Yin^*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068651 - 30 December 2025
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Objectives: Chromobox 4 (CBX4), a polycomb protein family member linked to tumor pathogenesis via dysregulation, has an incompletely defined role in gastric cancer (GC). The study aimed to investigate the role and mechanism of CBX4 in GC progression and evaluate its potential as a therapeutic target. Methods: CBX4 expression was assessed in GC tissues vs. adjacent non-cancerous tissues and in GC cell lines vs. normal gastric mucosal epithelial cells. Clinicopathological correlations were analyzed. Functional impacts of CBX4 were determined using knockdown and overexpression models in vitro (cell proliferation, migration, invasion) and in vivo (xenograft tumorigenesis in nude… More >

View

742

Download

248

Open Access

ARTICLE

Huihui Shi^1,#, Lei Chen^2,#, Juan Huang^3,#, Xuejing Lin², Lei Huang⁴, Min Tang⁴, Kai Lu^5,*, Wenchao Wang^4,*, Maoling Zhu^1,§,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068737 - 30 December 2025
（This article belongs to the Special Issue: Molecular Targets and Combinatorial Therapeutics of Liver Cancer)
Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. This study aimed to identify key genes involved in HCC development and elucidate their molecular mechanisms, with a particular focus on mitochondrial function and apoptosis. Methods: Differential expression analyses were performed across three datasets—The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC), GSE36076, and GSE95698—to identify overlapping differentially expressed genes (DEGs). A prognostic risk model was then constructed. Cysteine/serine-rich nuclear protein 1 (CSRNP1) expression levels in HCC cell lines were assessed via western blot (WB) and quantitative reverse transcription polymerase chain reaction (qRT-PCR).… More >

Graphic Abstract

View

656

Download

291

Open Access

ARTICLE

Yimin Liu^1,#, Bin Liu^2,3,4,#, Huabin Gao¹, Jinlong Wang⁵, Jingya Duan¹, Xiaolan Huang¹, Yuexi Liu¹, Ying Huang¹, Wenjing Liao¹, Ruonan Li^1,*, Hua Linghu^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069007 - 30 December 2025
（This article belongs to the Special Issue: Emerging Insights into the Tumor Microenvironment: Mechanisms, Therapeutic Targets, and Clinical Applications)
Abstract Objectives: High-grade serous ovarian cancer (HGSOC), the most common subtype of epithelial ovarian cancer (EOC), exhibits a mesenchymal phenotype characterized by fibrotic stroma and poor prognosis. Human epididymis protein 4 (HE4), a key diagnostic biomarker for ovarian cancer, is involved in fibrotic processes in several non-malignant diseases. Given the clinical significance of stromal fibrosis in HGSOC and the potential link between HE4 and fibrosis, this study aimed to investigate the role of HE4 in the formation of stromal fibrosis in HGSOC. Methods: A total of 126 patients with gynecological conditions were included and divided into… More >

Graphic Abstract

View

768

Download

303

Open Access

ARTICLE

Xu Guo¹, Yanan Yu², Xiaolin Ma³, Yuanjie Cai^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069274 - 30 December 2025
（This article belongs to the Special Issue: Long Non-coding RNAs (lncRNAs) and Cancer: A Focus on Four Key Areas)
Abstract Background: Long non-coding RNAs (lncRNAs) act as epigenetic regulators for tumor hallmarks. This investigation sought to probe the carcinogenic trait of PAN3-AS1 across pan-cancer comprehensively. Methods: We studied the diagnostic and prognostic features and the immune landscape of PAN3-AS1 across pan-cancer by bioinformatics approaches. The hierarchical regulatory networks governing PAN3-AS1 expression in colon cancer were explored via chromatin immunoprecipitation, luciferase activity assays, and RNA immunoprecipitation, etc. We screened drugs sensitive to WAP four-disulfide core domain 13 (WFDC13) by virtual screening and molecular docking. Results: Single-cell transcriptomics demonstrated that a variety of immune populations abnormally expressed PAN3-AS1… More >

View

322

Download

86

Open Access

ARTICLE

Kun Deng^1,2,3, Jianliang Huang^1,2,3, Danyang Li^2,3, Wei Gao^2,3, Minghua Wu^2,3,4,*, Mingsheng Lei^1,5,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069442 - 30 December 2025
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Background: Glioblastoma (GBM) prognosis has seen little improvement over the past two decades. While immunotherapy has revolutionized cancer treatment, its impact on GBM remains limited. To characterize the evolving research landscape and identify future directions in GBM immunotherapy, we conducted a comprehensive bibliometric review. Methods: All literature related to immunotherapy in GBM from 1999 to 2024 was collected from the Web of Science Core Collection. CtieSpace and VOSviewer were used to conduct bibliometric analysis and visualize the data. Results: Bibliometric analysis identified 5038 publications authored by 23,335 researchers from 4699 institutions across 96 countries/regions, published in… More >

View

548

Download

291

Open Access

ARTICLE

Yongle Qiu^1,#, Kunshan Li^1,#, Wenjing Wang¹, Wenjuan Zhang², Jilun Liu², Yang Bai³, Fei Xu³, Jie Guo^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069612 - 30 December 2025
（This article belongs to the Special Issue: Advances in Oral Cancer Treatment)
Abstract Background: The regulatory mechanisms governing vasculogenic mimicry (VM) in oral squamous cell carcinoma (OSCC) remain largely undefined. This study aimed to identify critical factors and elucidate the epigenetic mechanisms underlying VM in OSCC. Methods: Bioinformatics analysis was performed utilizing single-cell RNA-seq, bulk RNA-seq, and histone H3 lysine 27 acetylation (H3K27ac) Chromatin Immunoprecipitation (ChIP)-seq data obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. ChIP-qPCR was used to validate the binding of ETS transcription factor ELK4 (ELK4) to the dihydrofolate reductase (DHFR) enhancer. In vitro VM formation and invasion of OSCC cells were… More >

Graphic Abstract

View

180

Download

65

Open Access

ARTICLE

Lv Ling^1,#, Minying Lu^2,#, Ling Ye³, Yuanhang Chen², Sheng Lin², Jun Yang², Yu Rong^2,*, Guixiong Wu^4,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069889 - 30 December 2025
（This article belongs to the Special Issue: Novel Targets and Biomarkers in Solid Tumors)
Abstract Background: A significant proportion of patients still cannot benefit from existing targeted therapies and immunotherapies, making the search for new treatment strategies extremely urgent. In this study, we combined integrate public data analysis with experimental validation to identify novel prognostic biomarkers and therapeutic targets for lung adenocarcinoma (LUAD). Methods: We analyzed RNA and protein databases to assess the expression levels of cytochrome C oxidase 5B (COX5B) in LUAD. Several computational algorithms were employed to investigate the relationship between COX5B and immune infiltration in LUAD. To further elucidate the role of COX5B in LUAD, we utilized… More >

Graphic Abstract

View

339

Download

77

Open Access

ARTICLE

Jing Cai^1,#, Haoyun Zhu^1,#, Weiling Guo¹, Ting Huang¹, Pangzhou Chen^1,2, Wen Zhou¹, Ziyun Guan^1,3,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069902 - 30 December 2025
（This article belongs to the Special Issue: Recent Advances in Cancer Pharmacology)
Abstract Background: Therapeutic responses of breast cancer vary among patients and lead to drug resistance and recurrence due to the heterogeneity. Current preclinical models, however, are inadequate for predicting individual patient responses towards different drugs. This study aimed to investigate the patient-derived breast cancer culture models for drug sensitivity evaluations. Methods: Tumor and adjacent tissues from female breast cancer patients were collected during surgery. Patient-derived breast cancer cells were cultured using the conditional reprogramming technique to establish 2D models. The obtained patient-derived conditional reprogramming breast cancer (CRBC) cells were subsequently embedded in alginate-gelatin methacryloyl hydrogel microspheres… More >

View

466

Download

137

Open Access

ARTICLE

Kai Gui^1,#, Tianyi Yang^1,#, Chengying Xiong¹, Yue Wang¹, Zhiqiang He¹, Wuxian Li^2,3,*, Min Tang^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070143 - 30 December 2025
（This article belongs to the Special Issue: Machine Learning for Disease Subtyping, from Molecular to Clinical Features)
Abstract Objectives: The mechanism by which specific tumor subsets in colorectal cancer (CRC) use alternative metabolic pathways, particularly those modulated by hypoxia and fructose, to alter the tumor microenvironment (TME) remains unclear. This study aimed to identify these malignant subpopulations and characterize their intercellular signaling networks and spatial organization through an integrative multi-omics approach. Methods: Leveraging bulk datasets, single-cell RNA sequencing, and integrative spatial transcriptomics, we developed a prognostic model based on hypoxia-and fructose metabolism-related genes (HFGs) to delineate tumor cell subpopulations and their intercellular signaling networks. Results: We identified a specific subset of stanniocalcin-2 positive (STC2+)… More >

Graphic Abstract

View

462

Download

148

Open Access

ARTICLE

Tao Zhu¹, Taofeng Wei¹, Mingdong Yang¹, Junjun Xu¹, Huifang Jiang¹, Wei He¹, Juyan Zheng^2,*, Haibin Dai^1,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070180 - 30 December 2025
Abstract Background: Aberrant expression of transcription factors (TFs) is a key mechanism mediating tumor immune escape and therapeutic resistance. The involvement of E26 transformation-specific (ETS) family of TFs in immune regulation is not fully understood. The study aimed to elucidate the function of E-twenty-six variant 4 (ETV4) in tumor immune evasion and its potential as a predictive biomarker for immunotherapy in melanoma. Methods: The expression patterns of ETS family TFs were analyzed in melanoma and hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) was used to dissect the cellular expression and function of ETV4 in the tumor… More >

View

457

Download

183

Open Access

ARTICLE

Jianfa Wu^1,2,3, Huang Chen³, Sihong Wang^1,2, Lei Peng^1,2, Xiaoying Hu^1,2, Zhou Liu^1,2,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070542 - 30 December 2025
（This article belongs to the Special Issue: Identification of potential targets and biomarkers for cancers and the exploration of novel molecular mechanisms of tumorigenesis and metastasis)
Abstract Objectives: Ribosomal protein S6 kinase A2 (RPS6KA2) has been identified as a potential prognostic biomarker in several cancers, including breast cancer, glioblastoma, and prostate cancer. However, its functional significance in ovarian cancer is not well characterized. This study was designed to explore the therapeutic relevance of modulating RPS6KA2 in the context of ovarian cancer, particularly in relation to cisplatin resistance. Methods: The expression levels of RPS6KA2 and key regulators involved in autophagy and ferroptosis were assessed using quantitative reverse transcription-PCR, immunofluorescence staining, immunohistochemistry, and western blotting. Prognostic associations were conducted using the Kaplan-Meier Plotter database.… More >

View

280

Download

145

Open Access

ARTICLE

Shenghui Su, Yu Zeng, Jiaxin Chen, Xieping Dong^*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070558 - 30 December 2025
（This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)
Abstract Background: Recent studies have shown glycerolipid metabolism played an essential role in multiple tumors, however, its function in osteosarcoma is unclear. This study aimed to explore the role of glycerolipid metabolism in osteosarcoma. Methods: We conducted bioinformatics analysis using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database and single-cell RNA sequencing. Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to identify the Glycerolipid metabolism-related genes associated with the clinical outcome of osteosarcoma. Tumor-associated macrophages (TAMs) and their interactions with immune cells were examined through single-cell analysis and co-culture experiments.… More >

View

784

Download

283

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077268 - 30 December 2025
Abstract This article has no abstract. More >

View

16

Download

9

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077269 - 30 December 2025
Abstract This article has no abstract. More >

View

19

Download

10

Open Access

RETRACTION

Oncology Research Editorial Office
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077270 - 30 December 2025
Abstract This article has no abstract. More >

View

20

Download

11